55 related articles for article (PubMed ID: 23388474)
1. Involvement of hindbrain and peripheral prostanoids in gastric motor and cardiovascular responses to delta-9-tetrahydrocannabinol in the rat.
Krowicki ZK
J Physiol Pharmacol; 2012 Dec; 63(6):581-8. PubMed ID: 23388474
[TBL] [Abstract][Full Text] [Related]
2. Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine.
Cadoni C; Pisanu A; Solinas M; Acquas E; Di Chiara G
Psychopharmacology (Berl); 2001 Nov; 158(3):259-66. PubMed ID: 11713615
[TBL] [Abstract][Full Text] [Related]
3. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.
Krowicki ZK; Moerschbaecher JM; Winsauer PJ; Digavalli SV; Hornby PJ
Eur J Pharmacol; 1999 Apr; 371(2-3):187-96. PubMed ID: 10357256
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase inhibition in the dorsal vagal complex of the rat evokes increases in gastric motor function.
Krowicki ZK; Nathan NA; Hornby PJ
J Physiol Paris; 1997; 91(3-5):209-13. PubMed ID: 9403796
[TBL] [Abstract][Full Text] [Related]
5. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents.
Shook JE; Burks TF
J Pharmacol Exp Ther; 1989 May; 249(2):444-9. PubMed ID: 2542532
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacology of Delta9-tetrahydrocannabinol and its metabolite, 11-OH-Delta9-tetrahydrocannabinol.
Lemberger L; Martz R; Rodda B; Forney R; Rowe H
J Clin Invest; 1973 Oct; 52(10):2411-7. PubMed ID: 4729039
[TBL] [Abstract][Full Text] [Related]
7. Dose and behavioral context dependent inhibition of movement and basal ganglia neural activity by Delta-9-tetrahydrocannabinol during spontaneous and treadmill locomotion tasks in rats.
Shi LH; Luo F; Woodward DJ; Chang JY
Synapse; 2005 Jan; 55(1):1-16. PubMed ID: 15499609
[TBL] [Abstract][Full Text] [Related]
8. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol.
Solinas M; Zangen A; Thiriet N; Goldberg SR
Eur J Neurosci; 2004 Jun; 19(12):3183-92. PubMed ID: 15217374
[TBL] [Abstract][Full Text] [Related]
9. The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys.
Fredericks AB; Benowitz NL; Savanapridi CY
J Pharmacol Exp Ther; 1981 Feb; 216(2):247-53. PubMed ID: 6257883
[TBL] [Abstract][Full Text] [Related]
10. Vasoconstrictor actions of delta8- and delta9-tetrahydrocannabinol in the rat.
Adams MD; Earnhardt JT; Dewey WL; Harris LS
J Pharmacol Exp Ther; 1976 Mar; 196(3):649-56. PubMed ID: 4606
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats.
Kolb B; Gorny G; Limebeer CL; Parker LA
Synapse; 2006 Nov; 60(6):429-36. PubMed ID: 16881072
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and respiratory effects of cannabis in cat and rat.
Graham JD; Li DM
Br J Pharmacol; 1973 Sep; 49(1):1-10. PubMed ID: 4787563
[TBL] [Abstract][Full Text] [Related]
14. Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat.
Whitlow CT; Freedland CS; Porrino LJ
Psychopharmacology (Berl); 2002 May; 161(2):129-36. PubMed ID: 11981592
[TBL] [Abstract][Full Text] [Related]
15. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
D'Souza DC; Abi-Saab WM; Madonick S; Forselius-Bielen K; Doersch A; Braley G; Gueorguieva R; Cooper TB; Krystal JH
Biol Psychiatry; 2005 Mar; 57(6):594-608. PubMed ID: 15780846
[TBL] [Abstract][Full Text] [Related]
16. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol.
Butovsky E; Juknat A; Goncharov I; Elbaz J; Eilam R; Zangen A; Vogel Z
J Neurochem; 2005 May; 93(4):802-11. PubMed ID: 15857384
[TBL] [Abstract][Full Text] [Related]
17. [Delta-9-tetrahydrocannabinol pharmacokinetics].
Goullé JP; Saussereau E; Lacroix C
Ann Pharm Fr; 2008 Aug; 66(4):232-44. PubMed ID: 18847571
[TBL] [Abstract][Full Text] [Related]
18. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
Malone DT; Jongejan D; Taylor DA
Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive activity of Delta9-tetrahydrocannabinol non-ionic microemulsions.
Lazzari P; Fadda P; Marchese G; Casu GL; Pani L
Int J Pharm; 2010 Jun; 393(1-2):238-43. PubMed ID: 20399844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
